Metilfenidato Tecnigen (Methylphenidate Hydrochloride)

Methylphenidate blocks the reuptake of dopamine and norepinephrine at neuronal synapses, raising their levels in the brain. The increased catecholamine activity enhances attention, impulse control, and wakefulness, which underlies its therapeutic benefit in ADHD and narcolepsy.

The dosage of Metilfenidato Tecnigen is individualized. A qualified prescriber determines the appropriate strength, frequency, and duration based on the patient’s age, clinical response, and tolerability. Patients should follow the prescribing information provided by their healthcare professional.

Safety data for methylphenidate in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Methylphenidate, the active ingredient in Metilfenidato Tecnigen, is a dopamine‑norepinephrine reuptake inhibitor, whereas amphetamine‑based stimulants increase release of these neurotransmitters. Both classes improve ADHD symptoms, but individual response, side‑effect profile, and duration of action may differ, making personalized selection important.

Metilfenidato Tecnigen should be stored at room temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture, direct sunlight, and excessive heat to maintain stability and potency.

The medication is taken orally, usually as a tablet or capsule, with or without food as directed by the prescriber. Swallow the dose whole; do not crush, chew, or split unless specifically instructed by a healthcare professional.

Serious risks include cardiovascular events such as hypertension or arrhythmia, emergence of psychotic symptoms, severe allergic reactions, and rare occurrences of priapism or worsening of tics. Patients should be monitored closely for these events, especially during treatment initiation or dose changes.

Individuals with known hypersensitivity to methylphenidate or any component of the formulation should avoid the product. It is also contraindicated in patients taking monoamine oxidase inhibitors, those with severe cardiovascular disease, or uncontrolled psychiatric disorders without appropriate supervision.